一个无信息价值的真相：阿玛林公司药品未贴标签推广的逻辑
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
作者信息
Hey Spencer Phillips, Kesselheim Aaron S
机构信息
The Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.
The Harvard Center for Bioethics, Harvard Medical School, Boston, Massachusetts, United States of America.
出版信息
PLoS Med. 2016 Mar 15;13(3):e1001978. doi: 10.1371/journal.pmed.1001978. eCollection 2016 Mar.
Abstract
Spencer Phillips Hey and Aaron Kesselheim propose that informativeness-asserting scientific facts-rather than truthfulness ought to be the standard for regulating commercial speech about pharmaceuticals.
摘要
斯宾塞·菲利普斯·黑伊和亚伦·凯塞尔海姆提出，对于规范有关药品的商业言论而言，应当以提供信息——陈述科学事实——而非真实性作为标准。
相似文献
1
An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.
PLoS Med. 2016 Mar 15;13(3):e1001978. doi: 10.1371/journal.pmed.1001978. eCollection 2016 Mar.
2
Free Speech and Pharmaceutical Regulation -- Fishy Business.
JAMA Intern Med. 2016 Mar;176(3):295-6. doi: 10.1001/jamainternmed.2015.8155.
3
Assessing the clinical benefits of lipid-disorder drugs.
N Engl J Med. 2014 Jan 30;370(5):396-9. doi: 10.1056/NEJMp1313866.
4
The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
JAMA. 2015 Nov 3;314(17):1795-6. doi: 10.1001/jama.2015.12045.
5
Regulating Off-Label Promotion - A Critical Test.
N Engl J Med. 2016 Dec 15;375(24):2313-2315. doi: 10.1056/NEJMp1611755. Epub 2016 Nov 2.
6
Off-label marketing and the First Amendment.
N Engl J Med. 2013 Jan 10;368(2):103-5. doi: 10.1056/NEJMp1214926. Epub 2012 Dec 12.
7
The limits of free speech.
Nature. 2012 Dec 20;492(7429):311. doi: 10.1038/492311a.
8
Pros and cons of off-label promotion investigations and prosecutions.
Food Drug Law J. 2006;61(3):577-83.
9
Randomized Study of Providing Evidence Context to Mitigate Physician Misinterpretation Arising From Off-Label Drug Promotion.
Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e006073. doi: 10.1161/CIRCOUTCOMES.119.006073. Epub 2019 Nov 11.
10
Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
N Engl J Med. 2009 Apr 9;360(15):1557-66. doi: 10.1056/NEJMhle0807695.
本文引用的文献
1
Free Speech and Pharmaceutical Regulation -- Fishy Business.
JAMA Intern Med. 2016 Mar;176(3):295-6. doi: 10.1001/jamainternmed.2015.8155.
2
The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
JAMA. 2015 Nov 3;314(17):1795-6. doi: 10.1001/jama.2015.12045.
3
Biomarkers, Risk Factors, and Risk: Clarifying the Controversy About Surrogate End Points and Clinical Outcomes.
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):457-9. doi: 10.1161/CIRCOUTCOMES.115.002245.
4
Forbidden and Permitted Statements about Medications--Loosening the Rules.
N Engl J Med. 2015 Sep 3;373(10):967-73. doi: 10.1056/NEJMhle1506365.
5
Indications for Omega-3 Long Chain Polyunsaturated Fatty Acid in the Prevention and Treatment of Cardiovascular Disease.
Heart Lung Circ. 2015 Aug;24(8):769-79. doi: 10.1016/j.hlc.2015.03.020. Epub 2015 Apr 3.
6
Assessing the clinical benefits of lipid-disorder drugs.
N Engl J Med. 2014 Jan 30;370(5):396-9. doi: 10.1056/NEJMp1313866.
7
Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
J Am Coll Cardiol. 2013 Oct 22;62(17):1580-4. doi: 10.1016/j.jacc.2013.07.023. Epub 2013 Jul 31.
8
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
Eur Heart J. 2013 May;34(17):1279-91. doi: 10.1093/eurheartj/eht055. Epub 2013 Feb 26.
9
Statins for the primary prevention of cardiovascular disease.
Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004816. doi: 10.1002/14651858.CD004816.pub5.
10
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.
Zotero 插件